PL3381451T3 - Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej - Google Patents

Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej

Info

Publication number
PL3381451T3
PL3381451T3 PL16840922.5T PL16840922T PL3381451T3 PL 3381451 T3 PL3381451 T3 PL 3381451T3 PL 16840922 T PL16840922 T PL 16840922T PL 3381451 T3 PL3381451 T3 PL 3381451T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
adiposite
localized
tissues
reduction
Prior art date
Application number
PL16840922.5T
Other languages
English (en)
Inventor
Yu-Fang Ling
Original Assignee
Caliway Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58186932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3381451(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2015/088340 external-priority patent/WO2016029870A1/zh
Application filed by Caliway Biopharmaceuticals Co., Ltd. filed Critical Caliway Biopharmaceuticals Co., Ltd.
Publication of PL3381451T3 publication Critical patent/PL3381451T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16840922.5T 2015-08-28 2016-08-26 Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej PL3381451T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2015/088340 WO2016029870A1 (zh) 2014-08-28 2015-08-28 用于减少局部脂肪与减少体重的组合物及其医药品与应用
US201562257846P 2015-11-20 2015-11-20
US201662299702P 2016-02-25 2016-02-25
PCT/IB2016/055102 WO2017037594A2 (zh) 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途

Publications (1)

Publication Number Publication Date
PL3381451T3 true PL3381451T3 (pl) 2025-11-12

Family

ID=58186932

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16840922.5T PL3381451T3 (pl) 2015-08-28 2016-08-26 Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej

Country Status (26)

Country Link
US (4) US10610496B2 (pl)
EP (3) EP4647070A3 (pl)
JP (5) JP7063803B2 (pl)
KR (4) KR102356390B1 (pl)
CN (4) CN115778928B (pl)
AU (5) AU2016314546C1 (pl)
BR (2) BR112018003877A2 (pl)
CA (2) CA2995155C (pl)
CO (1) CO2018003424A2 (pl)
DK (1) DK3381451T3 (pl)
ES (1) ES3041835T3 (pl)
FI (1) FI3381451T3 (pl)
HR (1) HRP20251142T1 (pl)
HU (1) HUE072802T2 (pl)
IL (1) IL257784B2 (pl)
LT (1) LT3381451T (pl)
MX (3) MX384073B (pl)
PL (1) PL3381451T3 (pl)
PT (1) PT3381451T (pl)
RS (1) RS67518B1 (pl)
RU (1) RU2753507C2 (pl)
SG (1) SG11201801111RA (pl)
SI (1) SI3381451T1 (pl)
SM (1) SMT202500365T1 (pl)
TW (3) TWI630922B (pl)
WO (2) WO2017037594A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537548B2 (en) 2014-08-28 2020-01-21 Caliway Biopharmaceuticals Co., Ltd. Composition and medical product for reducing body weight and body fat, and use of said product
TWI630922B (zh) * 2015-08-28 2018-08-01 康霈生技股份有限公司 用於減少局部脂肪的醫藥組成物及其用途
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
EP3505168A1 (en) 2016-08-26 2019-07-03 Caliway Biopharmaceuticals Co., Ltd. Subcutaneous injection for reducing body weight and application thereof
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
EP3603628A4 (en) * 2017-03-28 2020-12-02 Caliway Biopharmaceuticals Co., Ltd. COMPOSITION OF WEIGHT REDUCTION AND BODY FAT REDUCTION AND CORRESPONDING PHARMACEUTICAL PRODUCT AND APPLICATION
CA3127506A1 (en) 2019-02-11 2020-08-20 Joseph Halstead Therapeutically administrable high dose non-aqueous curcuminoid solutions
EP3946407A4 (en) * 2019-03-24 2022-12-28 Patel, Naishadhkumar Ramubhai Formulation to enhance the bioavailibity and stability of curcuminoids and/or its derivatives thereof
CN110934827B (zh) * 2019-11-08 2021-03-19 江西中医药大学 一种口服葛根素混合胶束制剂、制备方法及应用
CN113730650B (zh) * 2021-10-13 2022-11-01 哈尔滨泽润医疗机构管理有限公司 一种碳水溶酶组合物及其制备方法和应用
KR102691705B1 (ko) * 2021-10-25 2024-08-06 주식회사 지엘케이인터내셔날 지방 분해용 조성물
WO2023192259A1 (en) * 2022-03-28 2023-10-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synergy for increasing insulin sensitivity
US12111372B2 (en) 2022-04-25 2024-10-08 GE Precision Healthcare LLC Wireless coil adaptor for a magnetic resonance imaging system
AU2023272056A1 (en) * 2022-05-16 2024-10-31 Caliway Biopharmaceuticals Co., Ltd. Compositions and methods for alleviating conditions caused by abnormal subcutaneous deposit of adipose tissue or fat
CN120225184A (zh) * 2022-11-22 2025-06-27 康霈生技股份有限公司 用于治疗和/或预防水肿性纤维硬化性脂膜病的方法
WO2025231431A1 (en) * 2024-05-03 2025-11-06 Amalfi Bio, Inc. Methods for reducing fatty infiltration

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
HK1040062A1 (zh) * 1999-03-03 2002-05-24 Eli Lilly And Company 含有成胶束表面活性剂的棘白菌素药物配方
ES2275463T3 (es) * 1999-08-16 2007-06-16 Dsm Ip Assets B.V. Proceso para la produccion de galato de epigalocatequina.
US6475530B1 (en) 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US20040071799A1 (en) 2001-02-12 2004-04-15 Xiurong Xu Herbal compositions and methods for effecting weight loss in humans
JP4179494B2 (ja) 2001-10-23 2008-11-12 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
DE602004022806D1 (de) 2003-06-04 2009-10-08 Nestec Sa Getränk zur gewichtskontrolle
CN100539988C (zh) * 2003-06-27 2009-09-16 株式会社太平洋 含有生理活性成分的自聚集聚合物纳米颗粒和含有该纳米颗粒的外用搽剂
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050232974A1 (en) * 2004-04-19 2005-10-20 Gore Makarand P System and a method for pharmaceutical dosage preparation using jettable microemulsions
WO2005113069A2 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
CN100486567C (zh) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 姜黄素乳剂及其制备方法
US20060188590A1 (en) 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
EP2520183B1 (de) * 2005-02-04 2017-07-05 Peter Heger Verwendung einer hydroxystilben-haltigen Wirkstoffkombination zur Behandlung von Depressionen und Angstzuständen
ITFI20050031A1 (it) 2005-02-21 2006-08-22 Stefan Coccoloni Una composizione farmaceutica atta a prevenire l'invecchiamento e l'insorgere di malattie vascolari,neoplastiche,cutanee e dell'apparato pilifero
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
JP2007063137A (ja) * 2005-08-29 2007-03-15 Daicho Kikaku:Kk 抗肥満薬
WO2007041276A2 (en) 2005-09-29 2007-04-12 New Chapter, Inc. Methods for modulating apoptosis, cellgrowth, and protein expression with herbal compositions
JP2007131603A (ja) 2005-11-14 2007-05-31 Kaneka Corp Ｌ−カルニチン合成系酵素遺伝子の転写促進用組成物
CN100367951C (zh) * 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
WO2007103435A2 (en) * 2006-03-06 2007-09-13 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
EA200802090A1 (ru) 2006-03-31 2010-04-30 ДСМ АйПи АССЕТС Б.В. Новое применение соединений и комбинаций соединений для улучшения внешнего вида
US7977319B1 (en) 2006-04-03 2011-07-12 Scott David Levine Ultra-high fiber supplement and method of reducing weight, cardiovascular risks and ingested toxins
WO2007113008A2 (en) * 2006-04-04 2007-10-11 Dsm Ip Assets B.V. Opaque container comprising food or pharmaceutical products or herbal(s)
CN101095665A (zh) * 2006-06-27 2008-01-02 中国科学院上海生命科学研究院 Sirt1在预防、控制或治疗肥胖中的用途
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
KR101069502B1 (ko) * 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
CN101310718A (zh) * 2007-05-23 2008-11-26 中国科学院上海生命科学研究院 减肥降血脂的含儿茶素的组合物及其用途
CN102357226B (zh) 2007-08-07 2013-07-10 北京北大维信生物科技有限公司 中草药姜黄的醇提取物在制备具有脂肪酶活性抑制作用的药物中的应用
WO2009066303A2 (en) 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
WO2009089011A2 (en) * 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
US20110268688A1 (en) * 2008-06-25 2011-11-03 Mccarthy James Timothy Method and compositions for improving skin and body appearance
US20100215782A1 (en) 2008-10-22 2010-08-26 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
US8496974B2 (en) * 2008-11-25 2013-07-30 Oy Granula Ab Ltd Method for preparing a composition comprising a compound mixture and a carrier agent
CA2748344A1 (en) * 2008-11-26 2010-06-03 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
RU2532384C2 (ru) * 2009-03-20 2014-11-10 Байокстракт С.А. Фармацевтическая композиция, проявляющая противовоспалительные свойства
CN101874763A (zh) * 2009-04-29 2010-11-03 上海家化联合股份有限公司 一种白藜芦醇柔性脂质体及其制备方法
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물
CN101632655B (zh) 2009-08-04 2011-12-07 南京大渊美容保健有限公司 延缓衰老的白藜芦醇和生物类黄酮营养组合物
JP5594819B2 (ja) 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
CN104771364B (zh) * 2010-03-10 2018-05-25 艾伯维巴哈马有限公司 固体组合物
US8835509B2 (en) * 2010-05-31 2014-09-16 Arbro Pharmaceuticals Ltd. Self emulsifying drug delivery system for a curcuminoid based composition
WO2012003515A2 (en) * 2010-07-02 2012-01-05 Eric Hauser Kuhrts Stable fatty acid-containing formulations
EP2588101B1 (en) 2010-07-02 2014-10-22 Helix Biomedix, Inc. N-acyl amino acid derivatives for treating skin conditions such as cellulite
KR101640258B1 (ko) * 2010-07-05 2016-07-15 주식회사 엘지생활건강 적포도 추출물, 녹차 추출물, 대두 추출물 및 ｌ－카르니틴을 유효성분으로 함유하는 항비만 조성물
WO2012007560A1 (en) 2010-07-16 2012-01-19 Merz Pharma Gmbh & Co. Kgaa Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue
US20120088829A1 (en) * 2010-09-29 2012-04-12 MyCell Holdings Limited Formulations of Ubiquinol and Resveratrol Esters
CN102106816A (zh) * 2010-12-16 2011-06-29 天津迈迪瑞康生物医药科技有限公司 一种白藜芦醇纳米制剂及其制备方法
US8815310B2 (en) 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
CN102512404B (zh) 2011-11-18 2014-05-07 上海交通大学 一种姜黄素类化合物肺靶向制剂及其制备方法与应用
JP6417630B2 (ja) 2011-12-27 2018-11-07 株式会社常磐植物化学研究所 サーチュイン活性化剤
ES2739194T3 (es) * 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
US8496979B1 (en) 2012-02-02 2013-07-30 Reliv International, Inc. Caffeine-free dietary supplements for increasing energy and methods of administering the same
EP2819752A4 (en) 2012-02-29 2016-03-09 Avon Prod Inc USE OF MODULATORS OF CPT-1 AND ASSOCIATED COMPOSITIONS
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
WO2014025672A1 (en) 2012-08-04 2014-02-13 Eric Hauser Kuhrts Water-soluble lipophilic natural compound formulations
WO2014028607A1 (en) * 2012-08-14 2014-02-20 Abbott Laboratories Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics
US9211298B2 (en) 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
DE202012012130U1 (de) * 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
WO2014138426A2 (en) * 2013-03-07 2014-09-12 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN103285401A (zh) * 2013-05-27 2013-09-11 沈阳药科大学 一种能提高难溶性药物溶解性和生物利用度的组合物
US9458086B1 (en) * 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
WO2015072602A1 (ko) 2013-11-15 2015-05-21 (주)다미화학 난용성 물질의 수용액 가용화 조성물 및 이를 이용한 난용성 물질의 수용액 가용방법
WO2015081319A2 (en) * 2013-11-27 2015-06-04 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
TW201540294A (zh) * 2014-04-25 2015-11-01 康立為生醫科技股份有限公司 用於抑制脂肪細胞、降低體脂肪、減少體重或促進脂肪代謝之植物萃取組成物及其醫藥組合物與用途
CN103989659B (zh) * 2014-05-26 2016-09-07 重庆医科大学 姜黄素纳米结构脂质载体及其制备方法
CN106794215A (zh) 2014-08-28 2017-05-31 康霈生技股份有限公司 用于减少体重及减少体脂肪的组合物及其医药品与应用
US10226503B2 (en) 2014-08-28 2019-03-12 Caliway Biopharmaceuticals Co., Ltd. Plant extract composition for reducing topical fat and promoting weight loss as well as applications thereof
MX385905B (es) * 2014-08-28 2025-03-11 Caliway Biopharmaceuticals Co Ltd Composicion para reducir la grasa local y el peso corporal y sustancias farmaceuticas y uso de las mismas.
TWI630922B (zh) 2015-08-28 2018-08-01 康霈生技股份有限公司 用於減少局部脂肪的醫藥組成物及其用途
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
EP3505168A1 (en) 2016-08-26 2019-07-03 Caliway Biopharmaceuticals Co., Ltd. Subcutaneous injection for reducing body weight and application thereof

Also Published As

Publication number Publication date
CN108697668B (zh) 2022-11-04
KR20180039167A (ko) 2018-04-17
CN115778928B (zh) 2025-07-25
US20180243211A1 (en) 2018-08-30
CA2995158C (en) 2021-05-11
AU2016314546C1 (en) 2021-07-22
EP4647070A2 (en) 2025-11-12
JP2020128404A (ja) 2020-08-27
EP4647070A3 (en) 2026-01-21
BR112018003892A2 (pt) 2018-09-25
RS67518B1 (sr) 2025-12-31
JP7063804B2 (ja) 2022-05-09
RU2753507C2 (ru) 2021-08-17
BR112018003877A2 (pt) 2018-09-25
SMT202500365T1 (it) 2025-11-10
SI3381451T1 (sl) 2025-12-31
EP3381473A4 (en) 2019-10-09
HUE072802T2 (hu) 2025-12-28
EP3381451B1 (en) 2025-08-20
US11433034B2 (en) 2022-09-06
DK3381451T3 (da) 2025-10-06
AU2016314545A1 (en) 2017-11-16
CN119157850A (zh) 2024-12-20
RU2019108198A (ru) 2020-09-21
MX384073B (es) 2025-03-11
CN109069655A (zh) 2018-12-21
EP3381451A4 (en) 2019-10-09
CA2995158A1 (en) 2017-03-09
JP7054540B2 (ja) 2022-04-14
EP3381451A2 (en) 2018-10-03
SG11201801111RA (en) 2018-03-28
HRP20251142T1 (hr) 2025-11-21
TWI604859B (zh) 2017-11-11
AU2019246808B2 (en) 2021-01-28
JP7063803B2 (ja) 2022-05-09
FI3381451T3 (fi) 2025-10-10
EP3381473A2 (en) 2018-10-03
KR102356390B1 (ko) 2022-02-08
AU2016314546B2 (en) 2019-09-12
CO2018003424A2 (es) 2018-07-10
KR20200032768A (ko) 2020-03-26
ES3041835T3 (en) 2025-11-14
LT3381451T (lt) 2025-10-10
AU2019246808A1 (en) 2019-10-31
IL257784B1 (en) 2023-07-01
CN115778928A (zh) 2023-03-14
US12357588B2 (en) 2025-07-15
WO2017037593A3 (zh) 2018-08-23
MX2018002462A (es) 2018-06-19
KR20200049882A (ko) 2020-05-08
CN108697668A (zh) 2018-10-23
TW201806584A (zh) 2018-03-01
US20220362173A1 (en) 2022-11-17
US20200163906A1 (en) 2020-05-28
PT3381451T (pt) 2025-10-01
KR20180037058A (ko) 2018-04-10
CA2995155C (en) 2021-05-11
JP2018533545A (ja) 2018-11-15
JP2018531220A (ja) 2018-10-25
IL257784A (en) 2018-06-28
TWI630922B (zh) 2018-08-01
AU2019280037A1 (en) 2020-01-16
MX2021010359A (es) 2021-10-01
MX2018002461A (es) 2018-06-07
CN109069655B (zh) 2024-09-27
AU2016314546A1 (en) 2018-03-01
JP2020143091A (ja) 2020-09-10
TW201707685A (zh) 2017-03-01
RU2019108198A3 (pl) 2020-09-21
TWI667044B (zh) 2019-08-01
MX387266B (es) 2025-03-18
AU2016314545C1 (en) 2021-09-23
AU2019280037B2 (en) 2021-02-18
WO2017037594A3 (zh) 2018-08-23
AU2021202349A1 (en) 2021-05-13
KR102107917B1 (ko) 2020-05-08
AU2021202349B2 (en) 2022-12-08
US20180250243A1 (en) 2018-09-06
TW201707686A (zh) 2017-03-01
US10610496B2 (en) 2020-04-07
CA2995155A1 (en) 2017-03-09
WO2017037594A2 (zh) 2017-03-09
KR102240221B1 (ko) 2021-04-14
JP2019528297A (ja) 2019-10-10
IL257784B2 (en) 2023-11-01
JP7095903B2 (ja) 2022-07-05
AU2016314545B2 (en) 2019-07-11
WO2017037593A2 (zh) 2017-03-09

Similar Documents

Publication Publication Date Title
PL3381451T3 (pl) Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
PL3481846T3 (pl) 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
HUE071358T2 (hu) Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
PL3229794T3 (pl) Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
EP3117827A4 (en) Composition for vagina and use of the composition
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
HUE045025T2 (hu) Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére
IL251351B (en) Preparations for use in the treatment and prevention of surgical infections
IL269884B1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies